Datopotamab deruxtecan showed mOS of 14.6 months in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial September 18, 2024
Global Launch of Artemia Ph 3 Registration Study for Cancer Vaccine Tedopi® in 2L NSCLC Cancer Announced September 18, 2024
Encouraging results from expansion part of Ph 1/2 SOHO-01 study of BAY 2927088 in advanced HER2-mutant NSCLC announced September 17, 2024
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced NSCLC September 17, 2024
Ph 2 THIO-101 trial results show THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC September 17, 2024
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) show strong favorable OS trend versus osimertinib in EGFR-mutated advanced lung cancer September 10, 2024
Ivonescimab Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab in 1L PD-L1+ve Advanced NSCLC patients in China September 10, 2024
Ifinatamab Deruxtecan Continues to Demonstrate Promising ORR in Patients with Extensive-Stage SCLC in IDeate-Lung01 Ph 2 Trial September 10, 2024
Novel computational pathology-based TROP2 biomarker for Dato-DXd was predictive of clinical outcomes in patients with NSCLC in TROPION-Lung01 September 10, 2024
Ph 3 KEYNOTE-867 trial in NSCLC and KEYNOTE-630 Trial in cSCC to be discontinued based on DMC recommendations September 3, 2024
Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage NSCLC September 3, 2024
First patient enrolled in Ph 3 SOHO-02 trial of BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations September 3, 2024
European Commission Approves BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adult patients with advanced NSCLC with a BRAFV600E mutation September 3, 2024
European Commission approves RYBREVANT (amivantamab) + chemo for adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy September 3, 2024
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) approved in the U.S. for patients with EGFR-mutated advanced lung cancer August 27, 2024
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m NSCLC August 27, 2024
FDA grants Breakthrough Therapy Designation to GSK5764227 for R/R extensive-stage SCLC August 27, 2024
TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC August 27, 2024
Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage SCLC in the US August 22, 2024
FDA approves Imfinzi + chemo for treatment of adult patients with resectable early-stage (IIA-IIIB) EGFR/ALK WT NSCLC August 22, 2024
Ph 3 KeyVibe-008 Trial of Vibostolimab + Pembrolizumab in Patients With Extensive-Stage SCLC to be discontinued as per IDMC recommendations August 13, 2024
